成人5q脊髓性肌萎缩症诺西那生治疗中脑脊液与血清神经丝轻链的长期动态变化
这项回顾性研究基于德国8个中心的前瞻性数据,纳入113例接受诺西那生治疗的成人5q脊髓性肌萎缩症患者和52例神经科对照,采用Simoa法检测脑脊液与血清神经丝轻链。结果显示,患者基线神经丝轻链显著高于对照,治疗各间期较负荷期显著下降,提示其可能作为药效学反应标志物,但在无临床改善患者中的意义尚不确定。
要点
- 成人5q脊髓性肌萎缩症患者基线脑脊液与血清神经丝轻链均显著高于神经科对照。
- 诺西那生治疗各间期神经丝轻链较负荷期显著下降,但T13-T19间期血清神经丝轻链除外。
- 即使无临床改善的患者,超过50%在至T13-T19间期仍显示脑脊液和血清神经丝轻链下降。
核心结论
- 诺西那生治疗期间神经丝轻链下降,提示其可能作为成人5q脊髓性肌萎缩症的药效学反应标志物。
- 在未检测到临床改善的患者中,本研究无法确定神经丝轻链下降是更敏感的结果指标还是无临床意义。
研究设计与样本
- 回顾性研究,前瞻性收集数据,纳入来自德国8个中心的113例成人5q脊髓性肌萎缩症患者和52例神经科对照。
- 采用单分子阵列(Simoa)法检测脑脊液神经丝轻链(cNfL)和血清神经丝轻链(sNfL)浓度。
- 分析定义的治疗间期:T1-T4(负荷期至4个月)、T5-T8(至23个月)、T9-T12(至37个月)、T13-T19(至60个月)。
- 采用随机截距线性混合模型评估治疗期间神经丝轻链水平变化,时间和协变量作为固定效应。
主要发现
- 患者中位年龄35岁,女性占46%,治疗持续时间最长达60个月。
- 基线脑脊液神经丝轻链中位数585(IQR 428-787)pg/mL,血清神经丝轻链中位数11(IQR 8-14)pg/mL;对照组脑脊液神经丝轻链中位数420(IQR 323-662)pg/mL,血清神经丝轻链中位数8(IQR 6-12)pg/mL;组间差异脑脊液p=0.021,血清p=0.030。
- 与负荷期相比,T5-T8间期所有临床评分的中位差值最大:HFMSE差值0.6(IQR 0.1-1.4),p=0.017;RULM差值0.9(IQR 0.4-1.3),p<0.001;ALSFRS-R差值0.7(IQR 0.4-1.0),p<0.001;后续间期未见相应差异。
- 纵向分析显示,除T13-T19间期的血清神经丝轻链外,各治疗间期神经丝轻链浓度较负荷期均显著下降(p<0.05)。
- 在无临床改善(HFMSE差值≤0)的患者中,超过50%在至T13-T19间期仍显示脑脊液和血清神经丝轻链水平下降。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出,在未检测到临床改善的患者中,本研究无法确定神经丝轻链下降是更敏感的结果指标还是无临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The availability of disease-modifying therapies for 5q-associated spinal muscular atrophy (SMA) has heightened the need to identify suitable biomarkers. This study investigates neurofilament light chain (NfL) concentrations during long-term nusinersen treatment in adult SMA. METHODS: In a retrospective study of prospectively collected data, NfL concentrations in the CSF (cNfL) and serum (sNfL) were measured in patients with SMA from 8 German centers and in neurologic controls using a single-molecule array (Simoa) assay. NfL concentrations and clinical characteristics, including the clinical scores Hammersmith Functional Motor Scale Expanded (HFMSE), Revised Upper Limb Module (RULM), and Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), were analyzed for defined treatment intervals (T1-T4 [loading phase until 4 months], T5-T8 [until 23 months], T9-T12 [until 37 months], and T13-T19 [until 60 months]). Linear mixed models with a random intercept were used to assess the changes in NfL levels during treatment, considering time and covariates as fixed effects. RESULTS: One hundred thirteen adult patients with SMA (median age 35, 46% female), with a treatment duration of maximum 60 months, and 52 controls were included. At baseline, NfL concentrations were significantly higher in SMA {cNfL median, 585 (interquartile range [IQR] 428-787) pg/mL; sNfL, 11 (IQR 8-14) pg/mL} than in controls (cNfL, 420 [IQR 323-662] pg/mL; sNfL, 8 [IQR 6-12] pg/mL) (cNfL, p = 0.021; sNfL, p = 0.030). Median differences for all clinical scores were the highest for T5-T8 compared with the loading phase (Δ HFMSE, 0.6 [IQR 0.1-1.4], p = 0.017; Δ RULM, 0.9 [IQR 0.4-1.3], p < 0.001; Δ ALSFRS-R, 0.7 [IQR 0.4-1.0], p < 0.001), but not for subsequent intervals. Longitudinal analysis revealed a significant decrease of NfL concentrations during each treatment interval compared with the loading phase (p < 0.05, respectively) except for sNfL in T13-T19. Even among patients with no measurable clinical improvement (Δ HFMSE ≤ 0), more than 50% showed declining cNfL and sNfL levels up to T13-T19. DISCUSSION: NfL decreased during nusinersen treatment, suggesting its potential as a pharmacodynamic response marker in adult SMA. However, in patients without detectable clinical improvement, our study cannot determine whether they represent a more sensitive outcome measure or are not clinically meaningful.
引用
- Cordts I, Fuetterer C, Wachinger A, et al. Long-Term Dynamics of CSF and Serum Neurofilament Light Chain in Adult Patients With 5q Spinal Muscular Atrophy Treated With Nusinersen. Neurology. 2025. PMID: 39946662. doi:10.1212/WNL.0000000000213371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。